Nordic biotech gets Euro41.5m fund


Copenhagen - Nordic Biotech Advisors ApS (“Nordic Biotech”) have closed their second biotech fund the Nordic biotech Venture Fund II K/S with a committed capital of Euro41.5 million. A second closing is foreseen to take place within 12 months, and is expected to increase the fund size to Euro75-90 million. The fund will primarily invest in European biotech companies with a focus on drug development. “We are tremendously pleased with the support that our current investors show us by their joining our second endeavour,” says Dr. Christian Hansen, partner and co-founder of Nordic Biotech. The investors include the European Investment Fund, Vaekstfonden, LD Pensions, W Capital Management AB and H.Lundbeck A/S.
The first fund initiated by Nordic Biotech has invested in a number of rapidly developing biotech companies with compounds in early-, mid- and late-stage clinical development, and retains significant ownership stakes in most of them. Its prior investments include for instance infectious disease company Lifecycle Pharma A/S (Denmark), allergy vaccine company CuraLogic A/S (Denmark), gastrointestinal company Gastrotech Pharma A/S (Denmark), cancer play Biotica Technology Ltd. (UK) as well as the Swedish company Global Genomics AB.



Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...



Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...



Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...



Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...



Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...



Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...



Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...



Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...



Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...



Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2014 BIOCOM

Product of the week



All Events

Current issue

All issues